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implantable cardiac deﬁbrillator (ICD).Methods We prospectively enrolled 204 subjects with ischemic cardiomyopathy (LVEF 35%) eligible for primary prevention
ICDs. Positron emission tomography (PET) was used to quantify myocardial sympathetic denervation (11C-meta-
hydroxyephedrine [11C-HED]), perfusion (13N-ammonia) and viability (insulin-stimulated 18F-2-deoxyglucose). The
primary endpoint was SCA deﬁned as arrhythmic death or ICD discharge for ventricular ﬁbrillation or ventricular
tachycardia >240 beats/min.Results After 4.1 years follow-up, cause-speciﬁc SCA was 16.2%. Infarct volume (22  7% vs. 19  9% of left ventricle [LV])
and LVEF (24  8% vs. 28  9%) were not predictors of SCA. In contrast, patients developing SCA had greater
amounts of sympathetic denervation (33  10% vs. 26  11% of LV; p ¼ 0.001) reﬂecting viable, denervated
myocardium. The lower tertiles of sympathetic denervation had SCA rates of 1.2%/year and 2.2%/year, whereas the
highest tertile had a rate of 6.7%/year. Multivariate predictors of SCA were PET sympathetic denervation, left
ventricular end-diastolic volume index, creatinine, and no angiotensin inhibition. With optimized cut-points, the
absence of all 4 risk factors identiﬁed low risk (44% of cohort; SCA <1%/year); whereas 2 factors identiﬁed high
risk (20% of cohort; SCA w12%/year).Conclusions In ischemic cardiomyopathy, sympathetic denervation assessed using 11C-HED PET predicts cause-speciﬁc mortality
from SCA independently of LVEF and infarct volume. This may provide an improved approach for the identiﬁcation of
patients most likely to beneﬁt from an ICD. (Prediction of ARrhythmic Events With Positron Emission Tomography
[PAREPET]; NCT01400334) (J Am Coll Cardiol 2014;63:141–9) ª 2014 by the American College of Cardiology
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142and evaluated in an attempt to
better identify the patient pop-
ulation at highest risk of future
arrhythmic death (1,2). How-
ever, despite multiple large clin-
ical trials performed during the
last 30 years, left ventricular
ejection fraction (LVEF) remains
the only parameter clinically used
to distinguish high- and low-risk
groups. Based on this approach,
randomized trials have unequivo-
cally established the beneﬁt of
prophylactic implantable cardiac
deﬁbrillator (ICD) placement to
prevent arrhythmic death and
improve survival in patients with
a LVEF 35% (3–5). Neverthe-
less, the majority of patients never
require device therapy to prevent
a lethal ventricular arrhythmia.
The ability to identify risk ofarrhythmic death independently of LVEF could better target
therapy among current ICD candidates, as well as identify
patients with LVEF>35% who are at high risk of SCA (1,2).
Although the latter population has a lower rate of arrhythmic
death, it actually accounts for a larger number of arrhythmic
events (6).
Previous basic and clinical studies have demonstrated an
important role for sympathetic activation in the develop-
ment of lethal ventricular arrhythmias, and inhomogeneity
in myocardial sympathetic innervation may create a
myocardial substrate particularly vulnerable to arrhythmic
death (7). This inhomogeneity can reﬂect sympathetic
denervation from infarction, as well as reversible ischemia.
For example, in reperfused infarcts, the extent of sympa-
thetic denervation exceeds infarct volume and approximates
the entire area at risk of myocardial ischemia (8). In chronic
coronary disease, reversible ischemia (from angina or silent
ischemia) also creates inhomogeneity in myocardial
sympathetic innervation that is independent of infarction,
occurring in both stunned and hibernating myocardium
(9). Pre-clinical models of hibernating myocardium have
a high rate of arrhythmic death from spontaneous
ventricular tachycardia (VT)/ventricular ﬁbrillation (VF)
that develops in the absence of infarction and heart failure
(10), and 11C-meta-hydroxyephedrine (11C-HED) posi-
tron emission tomography (PET) demonstrates extensive
sympathetic denervation (11).
On the basis of these observations, we tested the hypothesis
that quantifying inhomogeneity in myocardial sympathetic
innervation and/or hibernating myocardium increased the
risk of arrhythmic death independently of LV function. The
PAREPET (Prediction of ARrhythmic Events with Positron
Emission Tomography) study was designed as an initial steptoward this goal evaluating primary prevention ICD candi-
dates with coronary artery disease (12).
Methods
The PAREPET trial, sponsored by the National Institutes of
Health, is a prospective, observational cohort study designed
to determine whether imaging hibernating and/or denervated
myocardium can predict arrhythmic death in ischemic
cardiomyopathy. This study was approved by the University at
Buffalo and Veterans Affairs Western New York Healthcare
System Institutional Review Boards. Methodological details
of the study have been published and are provided in the
Online Appendix (12).
Study design. The study population (n ¼ 204) included
patients with ischemic cardiomyopathy who were eligible
to receive a primary prevention ICD (pre-enrollment
LVEF 35% for Class II and 30% for Class I). They had
stable ischemic heart disease and heart failure on optimal
medical therapy, andwerenot considered candidates for coronary
revascularization. Exclusion criteria included a prior cardiac arrest
or ICD discharge, recent infarction (<30 days), or revasculariza-
tion (PCI<3 months; bypass grafting<1 year) (12).
Echocardiography and PET. Two-dimensional echocar-
diography (Sonos 7500, Philips Medical Inc., Andover,
Massachusetts) was performed on the day of PET imaging
as previously described (12,13). An echocardiographer
blinded to events quantiﬁed cardiac volumes, LVEF, and
mitral regurgitation, as recommended by the American
Society of Echocardiography.
The PET imaging was performed on a ECAT EXACT
HRþ (CTI, Knoxville, Tennessee) PET scanner (15.5 cm
axial ﬁeld-of-view; resolution w5.4 mm3 full-width-at-half-
maximum) (12,13). Sympathetic innervation was assessed
with 11C-HED [740 MBq], resting perfusion with 13NH3
[740 MBq], and viability with 18F-2-deoxyglucose (18FDG)
[241MBq] during a hyperinsulinemic-euglycemic clamp (13).
Attenuation correction was performed using a 68Ge rod source
(12,13). Of the planned 585 PET images, 96% were
completed and quantiﬁable with 176 subjects having complete
data. Results from imaging were not provided for patient
management. Radiation exposure was <12 mSv.
Quantitative PET analysis. Blinded analysis used Flow-
Quant (Ottawa Heart Institute, Ottawa, Ontario, Canada)
(13,14) and decay corrected reconstructed images (zoom 2;
Hann ﬁlter cutoff 0.3 cycles/pixel). Late uptake deﬁned the
left ventricle (LV) with bottle-brush sampling (15). Late
myocardial uptake was averaged from 4 frames of data for
each imaging set: 15 to 60 min after 11C-HED; 3 to 19 min
after 13NH3; 15 to 40 min after
18FDG. We normalized
myocardial activity to the highest 5% of sectors (496 sector
model) (15). Normal 13NH3 and
18FDG uptake were
80% of peak (12,14). Normal 11C-HED uptake was
considered 75% of peak, on the basis of the estimated ratio
of reduced versus normal 11C-HED retention fraction among
Table 1 Clinical Parameters and SCA
SCA
(n ¼ 33)
No SCA
(n ¼ 171) p Value
Demographic parameters
Age (yrs) 66  8 67  12 0.57
Female 0 (0) 21 (12) 0.07
Body mass index (kg/m2) 28.3  4.5 28.6  5.1 0.76
Body surface area (m2) 2.1  0$2 2.0  0$2 0.27
NYHA functional class 2.3  0.6 2.1  0.8 0.33
CCS angina class 1.8  0.7 1.8  0.7 0.48
Diabetes mellitus 17 (52) 78 (46) 0.67
Coronary revascularization 21 (64) 138 (81) 0.053
Cardiac rhythm (not sinus) 5 (16) 17 (10) 0.56
QRS duration (ms) 137  32 136  35 0.79
Medications
Beta-blockers 32 (97) 163 (95) 0.97
Amiodarone 3 (9) 16 (9) 0.78
Antiplatelet agents or warfarin 32 (97) 169 (99) 0.98
Angiotensin inhibition therapy 26 (79) 157 (92) 0.052
Aldosterone antagonists 14 (42) 67 (39) 0.88
Digoxin 13 (39) 66 (39) 0.91
Hemodynamic parameters
Systolic blood pressure
(mm Hg)
127  17 126  21 0.93
Heart rate (beats/min) 63  11 66  12 0.23
Rate pressure product
(beats/min $ mm Hg)
7,952  1,389 8,398  2,282 0.28
Laboratory parameters
Hematocrit (%) 39.3  5.3 41.0  5.8 0.11
Potassium (mEq/l) 4.3  0.6 4.3  0.4 0.83
Sodium (mEq/l) 139  3 139  3 0.26
Creatinine (mg/dl) 1.7  1.2 1.3  0.7 0.04
B-type natriuretic peptide
(ng/l)
741  694 412  479 0.001
Values are mean  SD or n (%).
CCS ¼ Canadian Cardiovascular Society; NYHA ¼ New York Heart Association; SCA ¼ sudden
cardiac arrest.
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143zones with normal resting ﬂow (16). All PET parameters
were expressed as % of LV. Infarcted and hibernating
myocardium were quantiﬁed from a mismatch analysis
between 13NH3 and
18FDG (14). To evaluate the potential
inﬂuence of global downregulation in 11C-HED uptake,
11C-HED retention was determined for the segment with
maximal 11C-HED uptake in each subject. 11C-HED
retention (min1) was calculated by dividing mean segment
activity from the late uptake image by the integrated arterial
activity (from 0 to 60 min) (11).
Classiﬁcation of events. Subjects were contacted at
3-month intervals to review interval ICD therapy, hospi-
talizations, and symptoms. The primary endpoint was
sudden cardiac arrest (SCA). This included arrhythmic
death or ICD discharge for VF or VT >240 beats/min (12).
The frequency of ICD discharge for these arrhythmias
approximates the reduction in mortality with an ICD
(12,17,18). Clinical notes and electrograms from ICD
discharges were independently reviewed.
We classiﬁed deaths (i.e., SCA, cardiac nonsudden and
noncardiac) using modiﬁed Hinkle-Thaler criteria (19,20).
Available details (i.e., medical records, witnesses, family,
death certiﬁcates), activity levels, and symptoms before death
were reviewed by 2 cardiologists. In the event of disagree-
ment, a consensus was reached with a third reviewer.
Cardiac transplantation and arrhythmic events with end-
stage heart failure or hospice care were classiﬁed as cardiac
nonsudden deaths (19). Revascularization procedures were
performed on 26 subjects after enrollment.
Statistical analyses. Data are presented as mean  SD.
Subjects with andwithout SCAwere comparedwith unpaired
Student t tests (continuous data) and chi-square test analysis
(categorical data). The time to SCA was analyzed graphically
using Kaplan-Meier plots and was tested using Cox propor-
tional hazard models and the log-rank statistic. Optimal
cut-points for continuous variables were determined retro-
spectively by values that maximized the log-rank statistic.
Stepwise selection was used to generate the optimal multi-
variate model to predict time to SCA from PET, demo-
graphics,medications, echocardiographic, hemodynamic, and
laboratory parameters. All statistical analyses were performed
with commercial software (Microsoft Excel version 2010,
[Microsoft, Redmond, Washington] and SAS version 9.1,
[SAS Institute Inc., Cary, North Carolina]).
Results
Table 1 summarizes demographic variables. Average LVEF
was 27  9%, age was 67  11 years, New York Heart
Association functional class was 2.1  0.8, and Canadian
Cardiovascular Society angina class was 1.8  0.7. There
were 21 women (10%). Diabetes was present in 47%,
78% had prior coronary revascularization, and 81% had
an ICD prior to an event. Medical therapy was very good,
with almost all subjects treated with anti-platelet therapy
or warfarin (99%), b-blockers (96%), and angiotensininhibition therapy (angiotensin-converting-enyzme inhib-
itor or angiotensin receptor antagonist, 90%).
PET quantiﬁcation of denervated, infarcted, and viable
myocardium. PET images from 2 representative subjects
comparing resting ﬂow (13NH3), viability (insulin-stimu-
lated 18FDG), and myocardial sympathetic innervation
(11C-HED) are shown in Figure 1. Quantitative image
analysis determined that the average infarct volume was
20  9% of the LV. In comparison, the average volume of
denervated myocardium was considerably larger, averaging
27  11% of the LV (p < 0.001 vs. infarcted), with 8  6%
of the LV denervated, but viable. Hibernating myocardium
(viable myocardium with reduced resting perfusion) was
uncommon, reﬂecting the high prevalence of prior revas-
cularization, and averaged 3  3% of the LV.
Clinical and imaging correlates of SCA. During a median
follow-up of 4.1 years (range: 2.5 to 7.2 years), there were 33
adjudicated sudden cardiac arrests. There were no differ-
ences between the 22 subjects with arrhythmic death versus
the 11 with ICD discharges for VF or VT >240 beats/min.
All SCA events occurred in men (p ¼ 0.06). Selected
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Figure 1 PET imaging of Flow, Viability, and Sympathetic Innervation
(A) A subject experiencing sudden cardiac arrest (SCA). There is a mismatch in infarct size (reduced 18F-2-deoxyglucose [18FDG]), which was smaller than the volume of
sympathetic denervation (reduced 11C-meta-hydroxyephedrine [11C-HED]). There was also reduced perfusion (13N-ammonia [13NH3]) with preserved
18FDG indicating hibernating
myocardium. In contrast, B shows a subject with matched reductions in ﬂow, infarct volume, and sympathetic denervation. ANT ¼ anterior; INF ¼ inferior; LAT ¼ lateral; PET ¼
positron emission tomography; SEP ¼ septum.
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144imaging parameters associated with SCA are summarized in
Table 2. Subjects developing SCA had signiﬁcantly larger
volumes of denervated and viable denervated myocardium,
whereas infarct volume and hibernating myocardium were
not different. Although the LVEF and LV mass were not
signiﬁcantly different, those who experienced SCA had
larger LV volume indices and more mitral regurgitation.
Among laboratory parameters, serum creatinine and B-type
natriuretic peptide (BNP) were higher in patients deve-
loping SCA (Table 1).
Quantitative imaging and SCA. The primary analysis of
the PAREPET study was the evaluation of PET imaging
parameters as continuous variables to predict time to SCA.The
cumulative event rate curves of tertiles for each PET parameter
are summarized in Figure 2. The volume of denervated
myocardium had the strongest correlation with SCA (p ¼
0.001) (Table 3). Patients in the highest tertile of sympathetic
denervationhad anSCAevent rate ofw6.7%/year,whereas the
intermediate and lowest tertiles had event rates of 2.2%/year
and 1.2%/year, respectively. Each 1% increase in the volume of
denervated myocardium was associated with a 5.7% increasein the risk of SCA. Similarly, the volume of viable denervated
myocardiumwas signiﬁcantly associated with the time to SCA
(p ¼ 0.025), with risk of SCA increasing by 6.7% for every
1% increase in viable, denervated myocardium. The ability of
denervated myocardium to predict SCA was not inﬂuenced
by any global downregulation in 11C-HED uptake. The
11C-HED retention in segments with maximal 11C-HED
uptake was 0.136  0.036 min1, with no difference among
those with and without subsequent SCA (0.134 
0.027min1 vs. 0.137 0.037min1; p¼ 0.69).Therewas no
signiﬁcant association between SCA and the volume of
infarcted or hibernating myocardium (Table 3).
Other parameters signiﬁcantly associated with SCA, as
continuous variables included larger LV end-diastolic and
end-systolic volume indices, elevated BNP, elevated creati-
nine, larger left atrial volume, lower LVEF, and elevated LV
mass index (p < 0.05 for each) (Table 3). In addition, SCA
was associated with no angiotensin inhibition therapy (23%
vs. 9%; p ¼ 0.02). Multivariate analysis of these continuous
and categorical variables revealed that denervated myocar-
dium remained an independent predictor of time to SCA, in
Table 2 Imaging Parameters in Subjects With SCA
SCA
(n ¼ 33)
No SCA
(n ¼ 171) p Value
PET parameters (% LV)
Denervated myocardium 33  10 26  11 0.001
Infarcted myocardium 22  7 19  9 0.18
Viable, denervated myocardium 10  6 7  5 0.02
Hibernating myocardium 3  2 3  3 0.50
Echocardiography
LV ejection fraction (%) 24  8 28  9 0.053
LV end-diastolic volume index (ml/m2) 107  28 86  30 <0.001
LV end-systolic volume index (ml/m2) 81  21 63  26 <0.001
LV mass index (g/m2) 167  37 150  48 0.07
Mitral regurgitation 2.0  1.2 1.6  1.1 0.04
Values are mean  SD.
LV ¼ left ventricle; SCA ¼ sudden cardiac arrest.
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145addition to LV end-diastolic volume index, creatinine, and
no angiotensin inhibition therapy.
Predictors of risk using optimized cut-points. A post-hoc
analysis was performed to determine the optimal cut-point for
each of the continuous predictors (Fig. 3). Time to SCA was
predicted by greater denervatedmyocardium (>37.6% of the
LV, 19% of subjects), larger LV end-diastolic volume index
(cut-point ¼ 99 ml/m2, 34% of subjects), elevated creati-
nine (cut-point ¼ 1.49 mg/dl, 26% of subjects) and noDenervated
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Figure 2 PET Parameters and SCA
Kaplan-Meier curves show the incidence of SCA for tertiles of PET-deﬁned myocardial sub
denervated myocardium, as well as viable denervated myocardium, predicted SCA. Neithe
Abbreviations as in Figure 1.angiotensin inhibition therapy (10% of subjects). For
example, less denervated myocardium (<37.6% LV) iden-
tiﬁed a large subgroup (81% of the cohort) at lower risk of
SCA [SCA rate of 3.0%/year (95% CI: 1.9% to 4.7%)
vs. 10.3%/year (95% CI: 6.2% to 16.1%); p ¼ 0.001].
Then we tested how well these dichotomized factors
could predict the risk of SCA. Figure 4 shows that the
presence of 0, 1, or 2 of these risk factors could identify
subgroups of subjects having signiﬁcantly different risks of
SCA (p < 0.001). Subjects having no high-risk predictor
represented 44% of the cohort and had a very low risk of
SCA (0.9%/year). In contrast, those with 1 risk factor (36%
of the cohort) had an SCA rate of 3.9%/year, and those
with 2 or more high risk factors (20% of the cohort) had
an annual risk of SCA of 11.7%/year.Discussion
Our results demonstrate that myocardial sympathetic
denervation quantiﬁed using 11C-HED PET imaging
identiﬁes patients with ischemic cardiomyopathy who are at
high risk of SCA. The risk of SCA in this primary
prevention population was dependent on the total volume of
denervated myocardium and was independent of other
imaging parameters, including LVEF, infarct volume, and
hibernating myocardium. Thus, quantifying the extent ofViable Denervated
Tertile
Low
Medium
High
0 1 2 3 4
Infarcted
Years)
p = 0.15
p = 0.02
strates (median follow-up 4.1 years). As continuous variables, the total volume of
r infarct volume nor hibernating myocardium was signiﬁcant as continuous variables.
Table 3 Signiﬁcant Predictors of Time to SCA
Variable
Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value
PET parameters (per 1% of LV)
Denervated myocardium 1.057 (1.023–1.092) 0.001 1.069 (1.023–1.117) 0.003
Viable, denervated myocardium 1.067 (1.008–1.130) 0.025
Infarcted myocardium 1.029 (0.990–1.069) 0.15
Hibernating myocardium 0.950 (0.822–1.099) 0.49
Other signiﬁcant parameters
LVEDV index (per ml/m2) 1.021 (1.011–1.032) <0.0001 1.030 (1.010–1.050) 0.003
LVESV index (per ml/m2) 1.022 (1.011–1.033) <0.0001
BNP (per ng/L) 1.001 (1.000–1.001) 0.0003
Creatinine (per mg/dl) 1.53 (1.21–1.95) 0.0005 2.30 (1.12–4.71) 0.023
LA volume (per ml) 1.011 (1.003–1.019) 0.010
No angiotensin inhibition therapy 2.88 (1.25–6.67) 0.014 4.31 (1.07–17.38) 0.040
LV ejection fraction (per 1%) 0.951 (0.913–0.990) 0.016
LV mass index (per g/m2) 1.007 (1.000–1.014) 0.038
BNP ¼ B-type natriuretic peptide; CI ¼ conﬁdence interval; HR ¼ hazard ratio; LA ¼ left atrial; LV ¼ left ventricular; LVEDV ¼ left ventricular end-
diastolic volume; LVESV ¼ left ventricular end-systolic volume; PET ¼ positron emission tomography; SCA ¼ sudden cardiac arrest.
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146myocardial sympathetic denervation may provide a novel
approach to identify a subgroup of patients with ischemic
cardiomyopathy who would derive the most beneﬁt from
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Figure 3 Predictors of SCA by Multivariate Analysis
Kaplan-Meier curves illustrating the incidence of SCA greater than and less than the optim
end-diastolic volume index (LVEDVI >99 ml/m2), creatinine (>1.49 mg/dl), and no angiote
multivariate analysis. ACEI/ARA ¼ angiotensin-converting-enzyme inhibitor/angiotensin reICD therapy as a surrogate for aborted arrhythmic
death. Currently, there is no consensus regarding which
ICD therapies provide an appropriate surrogate for
arrhythmic death in observational studies. The deviceBelow Cut-off
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Figure 4 SCA Risk Factor Model
Kaplan-Meier curves illustrating highly signiﬁcant differences in the incidence of
SCA in relation to the number of risk factors present (p < 0.0001). Subjects with
no risk factor (blue, 44% of cohort) had an annual rate of SCA <1%. With 2 or more
risk factors (red, 20% of cohort), the annual risk of SCA increased to w12%.
Patients with 1 risk factor (green, 36% of cohort) had an intermediate risk of SCA
(w4%/year). Abbreviations as in Figure 1.
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147therapies included in our primary endpoint were consider-
ably more restrictive than the prevailing approach in
contemporary observational imaging studies, which typically
include all appropriate ICD therapies (anti-tachycardia
pacing and ICD discharge) (21–23). Appropriate ICD
therapies occur at least 3 times as frequently as fatal
arrhythmic events (4,18), and self-terminating ventricular
arrhythmias may have substrates and triggers that differ from
those resulting in arrhythmic death (24). Our prospectively
deﬁned primary endpoint was SCA, which included adju-
dicated arrhythmic death and an ICD equivalent endpoint
on the basis of device therapies most clearly associated
with lethal ventricular arrhythmias (VF and VT >240 beats/
min). In the MADIT II (Second Multicenter Automatic
Deﬁbrillator Implantation Trial), the frequency of these
device therapies plus death in patients randomized to an
ICD (18.3% at 2 years) was similar to the rate of death in the
medically treated group (18% at 2 years) (17). Although this
analysis supports using these events as surrogates of
arrhythmic death in patients with an ICD (17,18), we
cannot exclude the possibility that this conservative deﬁni-
tion may have underestimated the rate at which arrhythmic
death would have occurred in our population.
Myocardial sympathetic innervation and SCA. Recent
studies have imaged global cardiac sympathetic innerva-
tion in heart failure using 123I-meta-iodobenzylguanidine
(MIBG). They have consistently shown an association
between reductions in MIBG uptake and endpoints re-
ﬂecting a variety of composite cardiovascular outcomes in
patients with heart failure (21,25–27). However, there is
disagreement regarding the preferred imaging parameter
(reduced heart-to-mediastinum [H/M] ratio vs. accelerated
tracer washout rate) and the added beneﬁt from regional
tracer quantiﬁcation. There is also a paucity of outcome data
for cause-speciﬁc mortality from SCA.In a small study of heart failure patients (LVEF <40%;
n ¼ 106, 52% ischemic cardiomyopathy), MIBG imaging
was shown to predict arrhythmic death, as well as pump
failure death and total cardiac mortality (26). Both the H/M
ratio and the washout rate predicted arrhythmic death, but
only the washout rate and LVEF remained independent
after multivariate analysis. In contrast to our study, subjects
taking beta-blockers, insulin, or those with signiﬁcant renal
dysfunction at entry were excluded. Thus, more than 97% of
our study population would have been excluded, raising
questions about generalizing these ﬁndings to risk stratiﬁ-
cation for SCA among contemporary heart failure patients.
A larger observational study (ADMIRE-HF [AdreView
Myocardial Imaging for Risk Evaluation in Heart Failure])
imaged 961 subjects with an LVEF 35% (66% with
ischemic cardiomyopathy) and New York Heart Association
functional class II/III heart failure symptoms (27). The
composite primary endpoint was heart failure progression
(hospitalization or clinical assessment), potentially life-
threatening arrhythmias (sustained VT, resuscitated cardiac
arrest, or any appropriate ICD therapy including anti-
tachycardia pacing), and cardiac death. A late H/M
ratio <1.6 (reﬂecting both denervated myocardium and
accelerated washout from increased sympathetic nerve
activity) was present inw80% of patients and predicted the
composite endpoint (hazard ratio: 2.5). Evaluating regional
sympathetic innervation and perfusion did not improve this
in comparison with the global H/M ratio (27). In contrast,
another study evaluating heart failure patients referred for an
ICD (n ¼ 116, 74% with ischemic cardiomyopathy) found
neither the MIBG H/M ratio nor the washout rate to be
predictors of appropriate ICD therapy (21). A semi-
quantitative defect score predicted ICD therapy, which is
consistent with our ﬁndings and supports the importance of
quantifying regional sympathetic neuronal function for risk
stratiﬁcation of arrhythmic death (21).
Imaging of myocardial ischemia and infarct volume to
predict SCA. Acute myocardial ischemia, ﬁbrosis, and
infarction have been demonstrated to be arrhythmogenic
substrates. For example, in a large cohort with coronary
disease referred for perfusion imaging, the extent of infarc-
tion plus ischemia (summed stress perfusion score) was the
only independent imaging parameter to predict arrhythmic
death (28). This is consistent with our study in that the
volume of denervated myocardium approximates the area at
risk for ischemia (8,11). Nevertheless, due to our study
design and the stable nature of symptoms in our subjects,
coronary anatomy was not evaluated, and we did not directly
assess the presence or extent of stress-induced ischemia at
enrollment. Therefore, the potential roles of inducible
ischemia and coronary disease progression in SCA in this
study are not deﬁned.
Cardiac magnetic resonance imaging (MRI) has facili-
tated the quantiﬁcation of infarct volume, as well as patchy
ﬁbrosis (“gray zone”) surrounding the infarct borders.
Although cause-speciﬁc mortality from arrhythmic death
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correlated scar volume with cardiac endpoints, including
appropriate ICD therapy (22,23,29). Some studies (22), but
not all (23,29), have shown that quantiﬁcation of the “gray
zone” improves risk prediction. Interestingly, the MRI “gray
zone” is similar in size to viable, denervated myocardium
assessed by PET (the difference between denervated and
infarcted myocardium). Thus, they may ultimately prove to
be assessing a similar substrate with increased risk of lethal
arrhythmias. Further studies comparing infarct volume,
“gray zone,” and denervated volume will be required to
determine whether the 2 approaches provide similar risk
stratiﬁcation for SCA.
Predictive model to assess the risk of SCA. Our post-hoc
multivariate analysis demonstrated that quantifying the
volume of denervated myocardium along with 3 other vari-
ables (LV end-diastolic volume index, creatinine, and an-
giotensin inhibition therapy) independently predicted
arrhythmic risk. Quantifying infarct size, LVEF, and BNP
(and other variables) did not improve the predictive model.
Although other parameters have been associated with
cardiovascular mortality, they either preferentially predict
progressive heart failure (as opposed to SCA), or their
prognostic information was superseded by the 4 independent
factors. Importantly, more than 40% of our study population
had none of the risk factors and were at very low risk with
an annual SCA rate of <1%. This is actually lower than the
rate of arrhythmic death in patients with CAD and an
LVEF between 35% and 50%, and these patients are
currently not candidates for an ICD. At the other extreme,
20% of our subjects had 2 risk factors and a high annual
SCA rate ofw12%. A limitation of this analysis relates to its
post-hoc nature, inclusion of multiple parameters that could
result in overﬁtting and the optimization of cut-points on
a modest sample size. Nevertheless, identiﬁcation of 4
independent predictors is reasonable in relation to the
number of observed events. Further studies will be needed to
prospectively validate the model, but because it is indepen-
dent of ejection fraction among those with moderate-to-
severe LV dysfunction, it could ultimately be useful to
improve the risk stratiﬁcation of a much larger number of
patients at risk of SCA (6).
Study limitations. Our study speciﬁcally excluded patients
with recent myocardial infarction, nonischemic cardiomy-
opathy, and those who had more preserved LV systolic
function. Thus, future prospective studies will be required to
identify whether PET imaging with 11C-HED can improve
risk stratiﬁcation for SCA in these groups.
Conclusions
Our results indicate that quantifying regional sympathetic
denervation with 11C-HED PET may provide a novel
approach to identify patients at high risk of arrhythmic
death, independent of LVEF. Although PET/computed
tomographic scanning is widely available, the use of11C-HED would be limited to centers in close proximity to
a cyclotron. Fortunately, 18ﬂuorine-labeled norepinephrine
analogs have a longer half-life that could facilitate broader
application (30). With the use of these, molecular imaging
of myocardial sympathetic denervation in those patients
who have ischemic cardiomyopathy may afford a new ap-
proach to improve the targeting of ICDs to those who are
at greatest risk of SCA.Acknowledgments
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